- Isomorphic Labs by Google promotes clinical trials with drugs developed by Artificial Intelligence.
- AlphaFold's technology has revolutionized protein prediction, facilitating the design of more effective drugs.
- Top-tier pharmaceutical partners and a multi-million-dollar investment support the project.
- The areas of oncology and immunology are prioritized with the goal of creating personalized treatments.
Modern medicine could be on the verge of a momentous turn thanks to the drive of Google and Isomorphic Labs, its subsidiary focused on biotechnology. In recent years, artificial intelligence has ceased to be just a promise for the future and is beginning to materialize into concrete applications that seek Cure diseases Previously untreatable or complex to treat, this new direction focuses on drug development through fully automated algorithmic processes.
The work of Isomorphic Labs has gained prominence since its spin-off from DeepMind in 2021, under the umbrella of Alphabet, Google's parent company. Its objective is clear: to make the creation of drugs designed by artificial intelligence and transfer these developments to human trials, advancing toward therapies that could change the quality of life across the planet.
First clinical trials with AI-designed drugs
After years of research in the laboratory, The first steps have already been taken to test drugs developed exclusively using artificial intelligence in humans.. Colin Murdoch, president of Isomorphic Labs and also linked to Google DeepMind, points out that there are currently teams working together with systems of IA at its London headquarters with the aim of creating treatments for diseases as serious as cancer.
This leap into clinical research is supported by collaborations with giants of the pharmaceutical sector, such as Novartis and Eli Lilly, who have shown their confidence in this approach. The financial backing is also overwhelming: in April 2025, Isomorphic Labs managed to close a financing round of 600 million led by Thrive Capital, demonstrating the sector's strength and interest in this technological venture.
The AlphaFold revolution as a driver of progress
The turning point came with Alpha Fold, the system developed by DeepMind that since 2020 allows predict the three-dimensional structure of proteins from their amino acid sequenceThis ability opened the door to precise molecular design, facilitating the identification of molecules with high therapeutic potential and reducing the long trial and error process that characterizes traditional pharmaceutical development.
Thanks to this technology, Isomorphic Labs researchers can virtually model thousands of compounds and focus on the most promising ones before moving them to human trials. This is a crucial advantage, as currently only about 10% of experimental drugs They are approved after years of research and a multi-million dollar investment.
Oncology and immunology, the current priorities
The Murdoch-led team has noted that attention is focused on two areas where treatment options remain limited: cancer and immunological diseases. The use of AI can enable progress towards therapies more adapted to the characteristics of each patient and significantly increase the speed of new drug development.
Combining pharmacologists and artificial intelligence experts allows us to address scientific challenges that until now seemed insurmountable, by opting for personalized and effective solutions. This approach can not only shorten There necessary from discovery to the arrival of a drug on the market, but also to reduce development costs and the probability of failure in advanced stages.
Ethical and technological challenges ahead
Despite the progress, the transparency in the operation of algorithms And the ethical issues associated with the use of artificial intelligence in healthcare pose significant challenges. There is also the challenge of translating the positive results achieved by AI in virtual models into clinical practice with real people, where the variables are much more complex.
Google has demonstrated its strength in technological innovation, both with projects to decipher DNA sequences and in the development of advanced AI models such as Gemini 2.5 Pro, which integrate capabilities that until recently seemed unattainable. However, it will be in the coming months and years that we will see whether artificial intelligence can truly mark a turning point in the fight against complex diseases.
For now, the support of the scientific community and the financial commitment leave no doubt that this line of research is at a crucial moment. The implementation of clinical trials that demonstrate the effectiveness of AI-designed treatments could transform medicine, making it faster, more accessible and more efficient in the fight against high-impact pathologies in today's society.
Passionate writer about the world of bytes and technology in general. I love sharing my knowledge through writing, and that's what I'll do on this blog, show you all the most interesting things about gadgets, software, hardware, tech trends, and more. My goal is to help you navigate the digital world in a simple and entertaining way.